Business
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program,” hosted by D. Boral Capital on September 30, 2025, at 10:00 AM Eastern Time. The discussion will bring together leading key opinion leaders (KOLs) in musculoskeletal d
About this update from Enlivex Ltd.
[{"type":"image","alt":"Enlivex Therapeutics Ltd","displaySize":"","headline":null,"caption":"Enlivex Therapeutics Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/738648dcca3c88be57f0963407d94f31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lp55OoyoIVpO2pUDVuohlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/738648dcca3c88be57f0963407d94f31","width":150,"height":42}},"lazy":false},{"type":"text","content":"Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program,” hosted by D. Boral Capital on September 30, 2025, at 10:00 AM Eastern Time. The discussion will bring together leading key opinion leaders (KOLs) in musculoskeletal disease, alongside Enlivex’s Vice Chairman and D. Boral’s Research Director. The September 30 KOL webinar will explore recent breakthroughs in treatment approaches discussing the positive Phase IIa topline data from Enlivex’s Allocetra™ program in moderate-to-severe knee osteoarthritis (KOA) patients. Data demonstrated clinically meaningful and highly statistically significant reduction in pain and improvements in function in idiopathic, age-related knee osteoarthritis patients, a large, underserved population.","length":1042,"tagName":"p"},{"type":"text","content":"Register now to reserve your spot for the webinar:","length":50,"tagName":"p"},{"type":"text","content":"https://dboralcapital.zoom.us/webinar/register/WN_2S_71t_kQa2KZXj5HMOL7w#/registration","length":86,"tagName":"p"},{"type":"text","content":"Date/Time: September 30, 2025, at 10:00 AM Eastern Time","length":60,"tagName":"p"},{"type":"text","content":"Exclusive panel members:","length":24,"tagName":"p"},{"type":"text","content":"Professor Ali Mobasheri Ph.D – Professor of Musculoskeletal Biology at the University of Oulu, Finland, and former President of the Osteoarthritis Research Society International (OARSI). He also advises the WHO on musculoskeletal health, has published over 400 scientific articles, and is r...